pSivida eyes Iluvian
Friday, 13 March, 2009
pSivida has reported good interim results in its Phase II study of the intra-vitreal insert Iluvien.
The 36-month open label study is being conducted by pSivida’s licensing partner Alimera Sciences and is being run concurrently with a Phase III trial of a corticosteroid in patients with diabetic macular oedema.
Data from the first 12 months showed no adverse events in lose dose patients while there was a small increase in intra-ocular pressure in high dose patients.
Iluvian delivers the drug fluocinolone acetonide directly into the eye. pSivida has licensed two other ophthalmic products, Retisert and Vitrasert, to Bausch & Lomb.
Inhaled form of blood thinner treats serious COVID infections
Heparin has traditionally been injected and used to treat blood clots, but the new study tested...
Next-gen therapies could treat high-grade gliomas
Government funding will enable researchers to test a suite of next-generation therapies they have...
Bacteriophage cocktail to combat superbugs
Entelli-02 is a five-phage cocktail designed specifically to target Enterobacter cloacae...
